Literature DB >> 18218194

Serum lipid profiles and their relationship to cardiovascular disease in the elderly: the PREV-ICTUS study.

José V Lozano1, Vicente Pallarés, Luis Cea-Calvo, José L Llisterri, Cristina Fernández-Pérez, Juan C Martí-Canales, Jose Aznar, Vicente Gil-Guillén, Josep Redón.   

Abstract

OBJECTIVE: To assess the relationship between different serum lipid profiles and the prevalence of established cardiovascular disease (CVD) in an elderly population. RESEARCH DESIGN AND METHODS: An analysis was undertaken of the PREV-ICTUS population-based study on Spanish subjects aged > or =60 years. The following definitions were used: abnormal LDL cholesterol (LDL-C): > or =130 mg/dl (> or =3.3 mmol/L), or > or =100 mg/dl (> or =2.5 mmol/L) in those with diabetes or CVD, or treatment with any hypolipidaemic drug; low HDL cholesterol (HDL-C): <40 mg/dl (<1 mmol/L) (men), or <50 mg/dl (<1.3 mmol/L) (women), and abnormal triglycerides (TG): > or =150 mg/dl (> or =1.7 mmol/L) or treatment with fibrates. We defined eight groups: A (normal lipid profile), B (isolated abnormal LDL-C), C (isolated abnormal TG), D (isolated low HDL-C), E (abnormal LDL-C and HDL-C), F (abnormal LDL-C and TG), G (abnormal TG and HDL-C), H (abnormal LDL-C, HDL-C and TG). A multivariate analysis was performed to assess the relationship between each lipid profile and CVD.
RESULTS: A total of 6010 subjects (mean age 71.7 years, 53.5% women, 73.2% with hypertension, 29.2% with diabetes mellitus, 24.3% with CVD), were included in the analysis. LDL-C elevation was present in 78.1%, 23.3% had low HDL-C and 35.7% abnormal TG. Combined dyslipidaemias were frequent (40.3%). Odds ratios (95% confidence intervals) for CVD, compared with those with a normal lipid profile, were 2.07 (1.24-3.46) for abnormal HDL-C (p = 0.005), 4.09 (3.10-5.39) for abnormal LDL-C; 6.41 (4.59-8.95) for abnormal LDL-C plus HDL-C, 5.33 (3.98-7.14) for abnormal LDL-C plus TG and 7.59 (5.51-10.5) for those with the three parameters altered (all p < 0.001). Compared with those with isolated LDL-C elevation, those with abnormal LDL-C plus HDL-C had 1.57 (1.30-1.97) higher odds of having CVD (p < 0.001), the figures being 1.30 (1.11-1.53) for those with abnormal LDL-C plus TG and 1.86 (1.52-2.28) for those with abnormal LDL-C, TG plus HDL-C (p < 0.001).
CONCLUSIONS: Lipid abnormalities are frequent in the elderly, and are associated with the presence of CVD. Low HDL-C and/or abnormal TG levels, when added to abnormal LDL-C, are associated with a higher prevalence of CVD, suggesting the advisability of a comprehensive lipid evaluation and treatment earlier in life.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18218194     DOI: 10.1185/030079908X273372

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  6 in total

1.  Effect of a Probiotic Preparation (VSL#3) on CardiovascularRisk Parameters in Critically-Ill Patients.

Authors:  Sarvin Sanaie; Mehrangiz Ebrahimi-Mameghani; Ata Mahmoodpoor; Kamran Shadvar; Samad Ej Golzari
Journal:  J Cardiovasc Thorac Res       Date:  2013-06-27

2.  Disturbed nitric oxide and homocysteine production are involved in the increased risk of cardiovascular diseases in the F1 offspring of maternal obesity and malnutrition.

Authors:  Y Y Moussa; S H Tawfik; M M Haiba; M I Saad; M Y Hanafi; T M Abdelkhalek; G A Oriquat; M A Kamel
Journal:  J Endocrinol Invest       Date:  2016-12-27       Impact factor: 4.256

3.  Prevalence of mixed dyslipidemia among Australian patients undergoing lipid-modifying therapy.

Authors:  David Colquhoun; Diana Chirovsky; Valsilisa Sazonov; Yadong A Cui; Baishali Ambegaonkar
Journal:  Exp Clin Cardiol       Date:  2013

4.  Association between lipoprotein cholesterol and future cardiovascular disease and mortality in older adults: a Korean nationwide longitudinal study.

Authors:  Seung Hee Kim; Ki Young Son
Journal:  Lipids Health Dis       Date:  2021-01-06       Impact factor: 3.876

5.  A multi-ethnic epigenome-wide association study of leukocyte DNA methylation and blood lipids.

Authors:  Min-A Jhun; Michael Mendelson; Rory Wilson; Rahul Gondalia; Roby Joehanes; Elias Salfati; Xiaoping Zhao; Kim Valeska Emilie Braun; Anh Nguyet Do; Åsa K Hedman; Tao Zhang; Elena Carnero-Montoro; Jincheng Shen; Traci M Bartz; Jennifer A Brody; May E Montasser; Jeff R O'Connell; Chen Yao; Rui Xia; Eric Boerwinkle; Megan Grove; Weihua Guan; Pfeiffer Liliane; Paula Singmann; Martina Müller-Nurasyid; Thomas Meitinger; Christian Gieger; Annette Peters; Wei Zhao; Erin B Ware; Jennifer A Smith; Klodian Dhana; Joyce van Meurs; Andre Uitterlinden; Mohammad Arfan Ikram; Mohsen Ghanbari; Deugi Zhi; Stefan Gustafsson; Lars Lind; Shengxu Li; Dianjianyi Sun; Tim D Spector; Yii-der Ida Chen; Coleen Damcott; Alan R Shuldiner; Devin M Absher; Steve Horvath; Philip S Tsao; Sharon Kardia; Bruce M Psaty; Nona Sotoodehnia; Jordana T Bell; Erik Ingelsson; Wei Chen; Abbas Dehghan; Donna K Arnett; Melanie Waldenberger; Lifang Hou; Eric A Whitsel; Andrea Baccarelli; Daniel Levy; Myriam Fornage; Marguerite R Irvin; Themistocles L Assimes
Journal:  Nat Commun       Date:  2021-06-28       Impact factor: 17.694

6.  Mixed dyslipidemias in primary care patients in France.

Authors:  Laurent Laforest; Baishali M Ambegaonkar; Thierry Souchet; Vasilisa Sazonov; Eric Van Ganse
Journal:  Vasc Health Risk Manag       Date:  2012-04-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.